

Replace the paragraph beginning at page 55, line 24, with the following rewritten paragraph:

24 EGFP-tagged Hsp47 FACS probe was generated through additional genetic engineering (Figure 8A). This enabled searching for both potential huHsp47 receptors and for CIK subsets expressing such Hsp47 binding proteins. FACS analysis of mature d₂₁ CIK with eGFP-tagged HuHsp47 as FACS probe for the FITC channel, with CE56-PE co-staining, is based on differences in the Hsp47 binding ability of the analyzed CIK. The eGFP tagged Hsp47 probe stained a quarter of mature CIK (26%).

In the claims:

Please cancel claims 1-15.

Add new claims 43-57.

43. A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide consisting of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

44. A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide comprising the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3)

45. A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence of a polypeptide fragment of SEQ ID NO:6, the polypeptide fragment of SEQ ID NO:6 comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

SubFI cont
46. A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide comprising the amino acid sequence AVLSAEQLR (SEQ ID NO:3)

47. A method for reducing immune-mediated damage to cells, tissues or organs comprising contacting a cell, tissue or organ with an immunoprotective amount of a polypeptide consisting essentially of the amino acid sequence AVLSAEQLR (SEQ ID NO:3).

48. The method according to any one of claims 43-47 wherein the immune-mediated damage is caused by an autoimmune disease.

49. The method according to any one of claims 43-47 wherein the immune-mediated damage is caused by graft-versus-host disease.

50. The method according to any one of claims 43-47 wherein the immune-mediated damage is caused by host-versus-graft disease.

51. The method according to any one of claims 43-47 wherein the immune-mediated damage is caused by CIK cells.

52. The method of any one of claims 43-47 wherein the immune-mediated damage is caused by non-MHC I restricted cytotoxic T lymphocytes.

53. The method of any one of claims 43-47 wherein the immune-mediated damage is caused by natural killer cells.

54. The method of any one of claims 43-47 wherein the contacting takes place *in vitro*.

55. The method of any one of claims 43-47 wherein the contacting takes place *in vivo*.

Applicant : Ernest G. Hope et al.
Serial No. : 09/382,088
Filed : August 24, 1999
Page : 5

Attorney's Packet No.: 12932-003001

25
56. The method of any one of claims ~~43-47~~ wherein the composition further comprises blefeldin A.

Conclude ^{F2} 57. The method of ~~f~~ any one of claims 43-47 further comprising contacting the cells, tissues or organs with a composition comprising blefeldin A.--
